Core Laboratories（HJ1）株式概要コアラボラトリーズ社は、米国内外の石油・ガス業界に貯留層特性と生産性向上に関するサービスと製品を提供している。 詳細HJ1 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長2/6過去の実績2/6財務の健全性6/6配当金0/6報酬収益は年間18.25%増加すると予測されています 過去5年間の収益は年間8.7%増加しました。 リスク分析財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見るHJ1 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€11.707.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-55m738m2016201920222025202620282031Revenue US$595.0mEarnings US$32.9mAdvancedSet Fair ValueView all narrativesCore Laboratories Inc. 競合他社Deutsche RohstoffSymbol: XTRA:DR0Market cap: €477.6mEnviTec BiogasSymbol: XTRA:ETGMarket cap: €320.8mDaldrup & SöhneSymbol: XTRA:4DSMarket cap: €134.7mFriedrich Vorwerk GroupSymbol: XTRA:VH2Market cap: €1.4b価格と性能株価の高値、安値、推移の概要Core Laboratories過去の株価現在の株価US$11.7052週高値US$16.8052週安値US$8.30ベータ1.01ヶ月の変化-16.43%3ヶ月変化-24.52%1年変化21.24%3年間の変化-46.82%5年間の変化-63.44%IPOからの変化7.22%最新ニュースお知らせ • May 02Core Laboratories Inc. Approves Cash Dividend, Payable on June 1, 2026Core Laboratories Inc. announced on April 29, 2026, the Board approved a cash dividend of $0.01 per share of common stock, payable on June 1, 2026, to shareholders of record on May 11, 2026.お知らせ • Apr 01Core Laboratories Inc., Annual General Meeting, May 12, 2026Core Laboratories Inc., Annual General Meeting, May 12, 2026. Location: hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United Statesお知らせ • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.お知らせ • Mar 04Core Laboratories Inc. announced delayed annual 10-K filingOn 03/03/2026, Core Laboratories Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 05Core Laboratories Inc. Approves a Cash Dividend, Payable on March 9, 2026On February 4, 2026, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock, payable on March 9, 2026, to shareholders of record on February 16, 2026.お知らせ • Jan 06Core Laboratories Inc. to Report Q4, 2025 Results on Feb 04, 2026Core Laboratories Inc. announced that they will report Q4, 2025 results After-Market on Feb 04, 2026最新情報をもっと見るRecent updatesお知らせ • May 02Core Laboratories Inc. Approves Cash Dividend, Payable on June 1, 2026Core Laboratories Inc. announced on April 29, 2026, the Board approved a cash dividend of $0.01 per share of common stock, payable on June 1, 2026, to shareholders of record on May 11, 2026.お知らせ • Apr 01Core Laboratories Inc., Annual General Meeting, May 12, 2026Core Laboratories Inc., Annual General Meeting, May 12, 2026. Location: hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United Statesお知らせ • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.お知らせ • Mar 04Core Laboratories Inc. announced delayed annual 10-K filingOn 03/03/2026, Core Laboratories Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 05Core Laboratories Inc. Approves a Cash Dividend, Payable on March 9, 2026On February 4, 2026, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock, payable on March 9, 2026, to shareholders of record on February 16, 2026.お知らせ • Jan 06Core Laboratories Inc. to Report Q4, 2025 Results on Feb 04, 2026Core Laboratories Inc. announced that they will report Q4, 2025 results After-Market on Feb 04, 2026お知らせ • Oct 23+ 1 more updateCore Laboratories Inc. Announces Earnings Guidance for Fourth Quarter 2025Core Laboratories Inc. announced earnings guidance for fourth quarter 2025. For the quarter, revenue is projected to range from $132,000,000 to $136,000,000, with operating income of $14,000,000 to $16,100,000, yielding operating margins of approximately 11%. EPS for the fourth quarter of 2025 is expected to be $0.18 to $0.22.お知らせ • Oct 01Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda.Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025. This acquisition will further enhance Core Lab’s presence to deliver the most comprehensive suite of reservoir laboratory services in the region and long-term, sustainable value for its clients and shareholders. Core Laboratories Inc. (NYSE:CLB) completed the acquisition of Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025.お知らせ • Sep 25Core Laboratories Inc. to Report Q3, 2025 Results on Oct 22, 2025Core Laboratories Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025お知らせ • Jul 24+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 25, 2025On July 23, 2025, Core Laboratories Inc. Board approved a cash dividend of $0.01 per share of common stock payable on August 25, 2025, to shareholders of record on August 4, 2025.お知らせ • Jun 30+ 3 more updatesCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth IndexCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth Indexお知らせ • Jun 25Core Laboratories Inc. to Report Q2, 2025 Results on Jul 23, 2025Core Laboratories Inc. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025お知らせ • Apr 24Core Laboratories Inc. Approves Cash Dividend, Payable on May 27, 2025On April 23, 2025, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 27, 2025, to shareholders of record on May 5, 2025.お知らせ • Apr 02Core Laboratories Inc., Annual General Meeting, May 21, 2025Core Laboratories Inc., Annual General Meeting, May 21, 2025. Location: at the hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United Statesお知らせ • Mar 25Core Laboratories Inc. to Report Q1, 2025 Results on Apr 23, 2025Core Laboratories Inc. announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 23, 2025お知らせ • Jan 30+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the First Quarter 2025Core Laboratories Inc. provided earnings revenue for the first quarter 2025. The Company's first quarter 2025 revenue is projected to range from $121,000,000 to $127,000,000, with operating income of $10,200,000 to $12,800,000, yielding operating margins of approximately 9%. As such, EPS for the first quarter of 2025 is expected to be $0.12 to $0.16.お知らせ • Jan 04Core Laboratories Inc. to Report Q4, 2024 Results on Jan 29, 2025Core Laboratories Inc. announced that they will report Q4, 2024 results After-Market on Jan 29, 2025Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €20.20, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 7x in the Energy Services industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €25.65 per share.Declared Dividend • Oct 28Third quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 4th November 2024 Payment date: 25th November 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 7%. Cash payout ratio: 4%.Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: US$0.25 (vs US$0.20 in 3Q 2023)Third quarter 2024 results: EPS: US$0.25 (up from US$0.20 in 3Q 2023). Revenue: US$134.4m (up 7.2% from 3Q 2023). Net income: US$11.7m (up 27% from 3Q 2023). Profit margin: 8.7% (up from 7.4% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Oct 24+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024Core Laboratories Inc. provided earnings guidance for the fourth quarter of 2024. The company’s fourth quarter 2024 revenue is projected to range from $128,500,000 to $135,500,000, with operating income of $14,800,000 to $17,700,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2024 is expected to be $0.20 to $0.25.Buy Or Sell Opportunity • Oct 23Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €15.90. The fair value is estimated to be €20.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 11% in 2 years. Earnings are forecast to grow by 123% in the next 2 years.お知らせ • Sep 25Core Laboratories Inc. to Report Q3, 2024 Results on Oct 23, 2024Core Laboratories Inc. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024Buy Or Sell Opportunity • Aug 06Now 43% undervaluedThe stock has been flat over the last 90 days, currently trading at €12.30. The fair value is estimated to be €21.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.Upcoming Dividend • Jul 31Upcoming dividend of US$0.01 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 26 August 2024. Payout ratio is a comfortable 7.9% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.8%).Declared Dividend • Jul 31Second quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 5th August 2024 Payment date: 26th August 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 8%. Cash payout ratio: 6%.お知らせ • Jul 25+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 26, 2024On July 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on August 26, 2024 to shareholders of record on August 5, 2024.お知らせ • Jun 26Core Laboratories Inc. to Report Q2, 2024 Results on Jul 24, 2024Core Laboratories Inc. announced that they will report Q2, 2024 results After-Market on Jul 24, 2024Declared Dividend • Apr 29First quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 3rd May 2024 Payment date: 28th May 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 5%. Cash payout ratio: 9%.お知らせ • Apr 26Core Laboratories Inc. Approves Cash Dividend, Payable on May 28, 2024On April 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 28, 2024 to shareholders of record on May 6, 2024.Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: US$0.068 (vs US$0.051 in 1Q 2023)First quarter 2024 results: EPS: US$0.068 (up from US$0.051 in 1Q 2023). Revenue: US$129.6m (up 1.0% from 1Q 2023). Net income: US$3.22m (up 36% from 1Q 2023). Profit margin: 2.5% (up from 1.8% in 1Q 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • Mar 26Core Laboratories Inc. to Report Q1, 2024 Results on Apr 24, 2024Core Laboratories Inc. announced that they will report Q1, 2024 results After-Market on Apr 24, 2024お知らせ • Mar 20Core Laboratories Inc., Annual General Meeting, May 08, 2024Core Laboratories Inc., Annual General Meeting, May 08, 2024, at 09:00 Central Daylight. Location: Hotel Zaza, Memorial City, 9787 Katy Freeway Houston Texas United States Agenda: To re-elect two current Class III Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2027 and until their successors shall have been duly elected and qualified; to ratify the appointment of KPMG LLP as the Company's independent registered public accountants for the year ending December 31, 2024; to approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis, and the compensation of the Company's named executive officers as disclosed pursuant to the U.S. Securities and Exchange Commission's compensation disclosure rules, including the compensation tables; and to discuss other matters.お知らせ • Feb 01+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on March 4, 2024On January 31, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on March 4, 2024 to shareholders of record on February 12, 2024.お知らせ • Nov 02+ 1 more updateCore Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023Core Laboratories Inc. provided consolidated earnings guidance for the fourth quarter of 2023. The company's fourth quarter 2023 revenue is projected to range from $125,000,000 to $132,000,000 and operating income of $13,800,000 to $17,300,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2023 is expected to be $0.17 to $0.23. The Company's fourth quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange.お知らせ • Oct 05Core Laboratories Inc. to Report Q3, 2023 Results on Nov 01, 2023Core Laboratories Inc. announced that they will report Q3, 2023 results After-Market on Nov 01, 2023Reported Earnings • Jul 27Second quarter 2023 earnings released: EPS: US$0.49 (vs US$0.15 in 2Q 2022)Second quarter 2023 results: EPS: US$0.49 (up from US$0.15 in 2Q 2022). Revenue: US$127.9m (up 5.8% from 2Q 2022). Net income: US$22.8m (up 223% from 2Q 2022). Profit margin: 18% (up from 5.8% in 2Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 04Core Laboratories Inc. Approves to Elect Curtis Anastasio as Class I DirectorCore Laboratories Inc. announced at the AGM held on June 28, 2023 that the company approved to elect Curtis Anastasio as Class I Director.お知らせ • Jun 28Core Laboratories Inc. to Report Q2, 2023 Results on Jul 26, 2023Core Laboratories Inc. announced that they will report Q2, 2023 results After-Market on Jul 26, 2023株主還元HJ1DE Energy ServicesDE 市場7D0.9%-2.7%2.0%1Y21.2%65.3%-0.1%株主還元を見る業界別リターン: HJ1過去 1 年間で65.3 % の収益を上げたGerman Energy Services業界を下回りました。リターン対市場: HJ1過去 1 年間で-0.1 % の収益を上げたGerman市場を上回りました。価格変動Is HJ1's price volatile compared to industry and market?HJ1 volatilityHJ1 Average Weekly Movement8.2%Energy Services Industry Average Movement5.6%Market Average Movement6.2%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.7%安定した株価: HJ1 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: HJ1の 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19363,300Larry Brunowww.corelab.comCore Laboratories Inc.は、米国内外の石油・ガス業界に油層特性と生産性向上に関するサービスと製品を提供している。貯留層分析事業と生産性向上事業を通じて事業を展開している。貯留層分析事業では、顧客の貯留層から原油やガスの生産性を向上させ、回収率を改善するために、石油貯留層の岩石や貯留層流体サンプルの特性評価を行う。また、原油や石油製品の特性を評価するためのラボベースの分析サービスやフィールドサービス、独自研究や共同研究、炭素回収・利用・貯留、地熱プロジェクト、採掘活動の評価・鑑定をサポートするサービスも提供している。生産性向上部門は、貯留層の坑井仕上げ、穿孔、刺激、生産、坑井放棄に関するサービスと製品を提供する。坑井仕上げの有効性を評価・監視し、石油増進回収プロジェクトの有効性を向上させるソリューションを開発するための統合診断サービスを提供している。同社は、販売代理店、技術セミナー、展示会、印刷広告、および代理店を通じて、製品のマーケティングと販売を行っている。コアラボラトリーズ社は1936年に設立され、テキサス州ヒューストンに本社を置いている。もっと見るCore Laboratories Inc. 基礎のまとめCore Laboratories の収益と売上を時価総額と比較するとどうか。HJ1 基礎統計学時価総額€545.03m収益（TTM）€24.97m売上高(TTM)€451.22m21.8xPER（株価収益率1.2xP/SレシオHJ1 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計HJ1 損益計算書（TTM）収益US$524.73m売上原価US$420.19m売上総利益US$104.54mその他の費用US$75.51m収益US$29.03m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.63グロス・マージン19.92%純利益率5.53%有利子負債／自己資本比率41.6%HJ1 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.3%現在の配当利回り6%配当性向HJ1 配当は確実ですか？HJ1 配当履歴とベンチマークを見るHJ1 、いつまでに購入すれば配当金を受け取れますか？Core Laboratories 配当日配当落ち日May 11 2026配当支払日Jun 01 2026配当落ちまでの日数11 days配当支払日までの日数10 daysHJ1 配当は確実ですか？HJ1 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 19:12終値2026/05/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Core Laboratories Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。30 アナリスト機関James WestBarclaysNicholas GreenBernsteinSaurabh PantBofA Global Research27 その他のアナリストを表示
お知らせ • May 02Core Laboratories Inc. Approves Cash Dividend, Payable on June 1, 2026Core Laboratories Inc. announced on April 29, 2026, the Board approved a cash dividend of $0.01 per share of common stock, payable on June 1, 2026, to shareholders of record on May 11, 2026.
お知らせ • Apr 01Core Laboratories Inc., Annual General Meeting, May 12, 2026Core Laboratories Inc., Annual General Meeting, May 12, 2026. Location: hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United States
お知らせ • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.
お知らせ • Mar 04Core Laboratories Inc. announced delayed annual 10-K filingOn 03/03/2026, Core Laboratories Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 05Core Laboratories Inc. Approves a Cash Dividend, Payable on March 9, 2026On February 4, 2026, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock, payable on March 9, 2026, to shareholders of record on February 16, 2026.
お知らせ • Jan 06Core Laboratories Inc. to Report Q4, 2025 Results on Feb 04, 2026Core Laboratories Inc. announced that they will report Q4, 2025 results After-Market on Feb 04, 2026
お知らせ • May 02Core Laboratories Inc. Approves Cash Dividend, Payable on June 1, 2026Core Laboratories Inc. announced on April 29, 2026, the Board approved a cash dividend of $0.01 per share of common stock, payable on June 1, 2026, to shareholders of record on May 11, 2026.
お知らせ • Apr 01Core Laboratories Inc., Annual General Meeting, May 12, 2026Core Laboratories Inc., Annual General Meeting, May 12, 2026. Location: hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United States
お知らせ • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.
お知らせ • Mar 04Core Laboratories Inc. announced delayed annual 10-K filingOn 03/03/2026, Core Laboratories Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 05Core Laboratories Inc. Approves a Cash Dividend, Payable on March 9, 2026On February 4, 2026, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock, payable on March 9, 2026, to shareholders of record on February 16, 2026.
お知らせ • Jan 06Core Laboratories Inc. to Report Q4, 2025 Results on Feb 04, 2026Core Laboratories Inc. announced that they will report Q4, 2025 results After-Market on Feb 04, 2026
お知らせ • Oct 23+ 1 more updateCore Laboratories Inc. Announces Earnings Guidance for Fourth Quarter 2025Core Laboratories Inc. announced earnings guidance for fourth quarter 2025. For the quarter, revenue is projected to range from $132,000,000 to $136,000,000, with operating income of $14,000,000 to $16,100,000, yielding operating margins of approximately 11%. EPS for the fourth quarter of 2025 is expected to be $0.18 to $0.22.
お知らせ • Oct 01Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda.Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025. This acquisition will further enhance Core Lab’s presence to deliver the most comprehensive suite of reservoir laboratory services in the region and long-term, sustainable value for its clients and shareholders. Core Laboratories Inc. (NYSE:CLB) completed the acquisition of Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025.
お知らせ • Sep 25Core Laboratories Inc. to Report Q3, 2025 Results on Oct 22, 2025Core Laboratories Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
お知らせ • Jul 24+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 25, 2025On July 23, 2025, Core Laboratories Inc. Board approved a cash dividend of $0.01 per share of common stock payable on August 25, 2025, to shareholders of record on August 4, 2025.
お知らせ • Jun 30+ 3 more updatesCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth IndexCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth Index
お知らせ • Jun 25Core Laboratories Inc. to Report Q2, 2025 Results on Jul 23, 2025Core Laboratories Inc. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025
お知らせ • Apr 24Core Laboratories Inc. Approves Cash Dividend, Payable on May 27, 2025On April 23, 2025, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 27, 2025, to shareholders of record on May 5, 2025.
お知らせ • Apr 02Core Laboratories Inc., Annual General Meeting, May 21, 2025Core Laboratories Inc., Annual General Meeting, May 21, 2025. Location: at the hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United States
お知らせ • Mar 25Core Laboratories Inc. to Report Q1, 2025 Results on Apr 23, 2025Core Laboratories Inc. announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 23, 2025
お知らせ • Jan 30+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the First Quarter 2025Core Laboratories Inc. provided earnings revenue for the first quarter 2025. The Company's first quarter 2025 revenue is projected to range from $121,000,000 to $127,000,000, with operating income of $10,200,000 to $12,800,000, yielding operating margins of approximately 9%. As such, EPS for the first quarter of 2025 is expected to be $0.12 to $0.16.
お知らせ • Jan 04Core Laboratories Inc. to Report Q4, 2024 Results on Jan 29, 2025Core Laboratories Inc. announced that they will report Q4, 2024 results After-Market on Jan 29, 2025
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €20.20, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 7x in the Energy Services industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €25.65 per share.
Declared Dividend • Oct 28Third quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 4th November 2024 Payment date: 25th November 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 7%. Cash payout ratio: 4%.
Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: US$0.25 (vs US$0.20 in 3Q 2023)Third quarter 2024 results: EPS: US$0.25 (up from US$0.20 in 3Q 2023). Revenue: US$134.4m (up 7.2% from 3Q 2023). Net income: US$11.7m (up 27% from 3Q 2023). Profit margin: 8.7% (up from 7.4% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Oct 24+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024Core Laboratories Inc. provided earnings guidance for the fourth quarter of 2024. The company’s fourth quarter 2024 revenue is projected to range from $128,500,000 to $135,500,000, with operating income of $14,800,000 to $17,700,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2024 is expected to be $0.20 to $0.25.
Buy Or Sell Opportunity • Oct 23Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €15.90. The fair value is estimated to be €20.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 11% in 2 years. Earnings are forecast to grow by 123% in the next 2 years.
お知らせ • Sep 25Core Laboratories Inc. to Report Q3, 2024 Results on Oct 23, 2024Core Laboratories Inc. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024
Buy Or Sell Opportunity • Aug 06Now 43% undervaluedThe stock has been flat over the last 90 days, currently trading at €12.30. The fair value is estimated to be €21.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.
Upcoming Dividend • Jul 31Upcoming dividend of US$0.01 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 26 August 2024. Payout ratio is a comfortable 7.9% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.8%).
Declared Dividend • Jul 31Second quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 5th August 2024 Payment date: 26th August 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 8%. Cash payout ratio: 6%.
お知らせ • Jul 25+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 26, 2024On July 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on August 26, 2024 to shareholders of record on August 5, 2024.
お知らせ • Jun 26Core Laboratories Inc. to Report Q2, 2024 Results on Jul 24, 2024Core Laboratories Inc. announced that they will report Q2, 2024 results After-Market on Jul 24, 2024
Declared Dividend • Apr 29First quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 3rd May 2024 Payment date: 28th May 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 5%. Cash payout ratio: 9%.
お知らせ • Apr 26Core Laboratories Inc. Approves Cash Dividend, Payable on May 28, 2024On April 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 28, 2024 to shareholders of record on May 6, 2024.
Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: US$0.068 (vs US$0.051 in 1Q 2023)First quarter 2024 results: EPS: US$0.068 (up from US$0.051 in 1Q 2023). Revenue: US$129.6m (up 1.0% from 1Q 2023). Net income: US$3.22m (up 36% from 1Q 2023). Profit margin: 2.5% (up from 1.8% in 1Q 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • Mar 26Core Laboratories Inc. to Report Q1, 2024 Results on Apr 24, 2024Core Laboratories Inc. announced that they will report Q1, 2024 results After-Market on Apr 24, 2024
お知らせ • Mar 20Core Laboratories Inc., Annual General Meeting, May 08, 2024Core Laboratories Inc., Annual General Meeting, May 08, 2024, at 09:00 Central Daylight. Location: Hotel Zaza, Memorial City, 9787 Katy Freeway Houston Texas United States Agenda: To re-elect two current Class III Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2027 and until their successors shall have been duly elected and qualified; to ratify the appointment of KPMG LLP as the Company's independent registered public accountants for the year ending December 31, 2024; to approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis, and the compensation of the Company's named executive officers as disclosed pursuant to the U.S. Securities and Exchange Commission's compensation disclosure rules, including the compensation tables; and to discuss other matters.
お知らせ • Feb 01+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on March 4, 2024On January 31, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on March 4, 2024 to shareholders of record on February 12, 2024.
お知らせ • Nov 02+ 1 more updateCore Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023Core Laboratories Inc. provided consolidated earnings guidance for the fourth quarter of 2023. The company's fourth quarter 2023 revenue is projected to range from $125,000,000 to $132,000,000 and operating income of $13,800,000 to $17,300,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2023 is expected to be $0.17 to $0.23. The Company's fourth quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange.
お知らせ • Oct 05Core Laboratories Inc. to Report Q3, 2023 Results on Nov 01, 2023Core Laboratories Inc. announced that they will report Q3, 2023 results After-Market on Nov 01, 2023
Reported Earnings • Jul 27Second quarter 2023 earnings released: EPS: US$0.49 (vs US$0.15 in 2Q 2022)Second quarter 2023 results: EPS: US$0.49 (up from US$0.15 in 2Q 2022). Revenue: US$127.9m (up 5.8% from 2Q 2022). Net income: US$22.8m (up 223% from 2Q 2022). Profit margin: 18% (up from 5.8% in 2Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 04Core Laboratories Inc. Approves to Elect Curtis Anastasio as Class I DirectorCore Laboratories Inc. announced at the AGM held on June 28, 2023 that the company approved to elect Curtis Anastasio as Class I Director.
お知らせ • Jun 28Core Laboratories Inc. to Report Q2, 2023 Results on Jul 26, 2023Core Laboratories Inc. announced that they will report Q2, 2023 results After-Market on Jul 26, 2023
